The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer
Open accessAbstract
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival of < 10% because of diffuse symptoms leading to late-stage diagnosis. That survival could increase significantly if localized tumors could be detected early. Therefore, we used multiparametric analysis of blood samples to obtain a novel biomarker signature of early-stage PDAC. The signature was derived from a large patient cohort, including patients with well-defined early-stage (I and II) PDAC. This biomarker signature was validated subsequently in an independent patient cohort. PATIENTS AND METHODS: The biomarker signature was derived from a case-control study, using a Scandinavian cohort, consisting of 16 patients with stage I, 132 patients with stage II, 65 patients with stage III, and 230 patients with stage IV PDAC, and 888 controls. This signature was validated subsequently in an independent case-control cohort in the United States with 15 patients with stage I, 75 patients with stage II, 15 patients with stage III, and 38 patients with stage IV PDAC, and 219 controls. An antibody microarray platform was used to identify the serum biomarker signature associated with early-stage PDAC. RESULTS: Using the Scandinavian case-control study, a biomarker signature was created, discriminating samples derived from patients with stage I and II from those from controls with a receiver operating characteristic area under the curve value of 0.96. This signature, consisting of 29 biomarkers, was then validated in an independent case-control study in the United States. The biomarker signature could discriminate patients with stage I and II PDAC from controls in this independent patient cohort with a receiver operating characteristic area under the curve value of 0.96. CONCLUSION: This serum biomarker signature might represent a tenable approach to detecting early-stage, localized PDAC if these findings are supported by a prospective validation study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 27,235
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2015) · BMJ · doi:10.1136/bmj.h5527 · Cited by 3,660
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00141-0 · Cited by 2,212
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S. R., Harris, J. E., Jessup, J. M., Kemeny, N. E., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,614
Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators
Riall, T. S., Yeo, C. J., Cameron, J. L., Koniaris, L. G., Kaushal, S., Abrams, R. A., Sauter, P. K., Coleman, J., Hruban, R. H., & Lillemoe, K. D. (2000) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(00)80105-5 · Cited by 1,482
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1016/j.gastro.2005.05.007 · DOI · Paper page
Cited by
Sorted by citations
Items 101–160 of 160
Fluorophore signal detection and imaging enhancement in high refractive index nanowire biosensors
Anttu, N. (2025) · Nano Express · doi:10.1088/2632-959x/adae27 · Cited by 6
Li, Y., Fan, Z., Meng, Y., Yang, J., Li, P., Liu, S., Pang, C., Du, L., Wang, Y., & Zhan, H. (2024) · Pancreatology · doi:10.1016/j.pan.2024.05.529 · Cited by 5
Blood-Based Biomarkers in the Diagnosis and Risk Stratification of Pancreatic Cysts
Peller, M. T., & Das, K. K. (2023) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2023.03.009 · Cited by 5
Kolokotronis, T., Majchrzak‐Stiller, B., Buchholz, M., Mense, V., Strotmann, J., Peters, I., Skrzypczyk, L., Liffers, S., Menkene, L. M., Wagner, M., et al. (2024) · Cancers · doi:10.3390/cancers16152726 · Cited by 5
“More importantly, unique serum/plasma miRNA expression profiles for PDAC can serve as fingerprints for their detection [16].”
BackgroundMethodPancreatic Cancer Prediction Machine Learning using Multi Fusion Model
Sathiyapriya, V., Devi, K. N., Deepa, S., Marimuthu, M., Manikandan, P., & Prabu, S. (2024) · International Conference on Distributed Systems, Computer Networks and Cybersecurity (ICDSCNC) · doi:10.1109/icdscnc62492.2024.10939888 · Cited by 5
“At last, it compared with different methods on novel DGLRM. [10] designed study of case-manage uses pre diagnostic blood glucose.”
Fridhammar, A., Axelsson, U., Persson, U., Bjartell, A. S., & Borrebaeck, C. A. K. (2020) · PharmacoEconomics - Open · doi:10.1007/s41669-020-00226-7 · Cited by 5
Shin, D. W., Cho, J., Cho, S., Youn, Y., & Hwang, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-19631-1 · Cited by 5
“…diagnostic biomarkers derived from various biological sources, including blood (e.g., extracellular vesicles 32,33 circulating tumor DNA [ctDNA] or cell-free DNA [cfDNA] 34,35 mRNA, microRNA [miR] 36 small nuclear RNA 37 long noncoding RNA 38 proteins 39 metabolites 40 , and pancreatic fluid 41 .”
Tong, T., Zhang, C., Li, J., Deng, M., & Wang, X. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.934974 · Cited by 4
Earl, J., Fuentes, R., Sanchez, M. E. C., de Paredes, A. G. G., Muñoz, M., Sanjuánbenito, A., Lobo, E., Caminoa, A., Rodríguez, M., Barreto, E., et al. (2024) · Familial Cancer · doi:10.1007/s10689-024-00388-x · Cited by 4
“However, the clinical application of the liquid biopsy is likely to be an integral part of cancer diagnostics and management in the near future, with several potential biomarkers for early detection reported in the scientific literature [36–39].”
BackgroundBiomarkers for the Early Detection of Pancreatic Ductal Adenocarcinoma
Borrebaeck, C. A. K., Mellby, L. D., & King, T. C. (2022) · Exon Publications eBooks · doi:10.36255/exon-publications-gastrointestinal-cancers-biomarkers-pancreatic-cancer · Cited by 4
Brofelth, M., Isinger-Ekstrand, A., Gour, S., Jansson, R., Hedhammar, M., Elleby, B., Kvist, A., Wingren, C., Axelsson, U., & Borrebaeck, C. A. K. (2020) · Communications Biology · doi:10.1038/s42003-020-1068-0 · Cited by 4
Korobkov, D., Molodtsov, I. A., Kononikhin, A. S., Bugrova, A. E., Indeykina, M. I., Brzhozovskiy, A. G., Kanner, D. Y., Николаев, Е. Н., Vasilieva, E., & Komissarov, A. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189219 · Cited by 3
Liu, Y., Khosravi, F., Yeo, D., Söderström, B., El-helou, A. J., Reece, P. J., Sharbeen, G., Phillips, P. A., & Zhu, Y. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00113 · Cited by 3
Gynecologic Cancer Screening and Prevention: State of the Science and Practice
Tran, C., Diaz-Ayllon, H. P., Abulez, D. S., Chinta, S., Williams‐Brown, M. Y., & Desravines, N. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01301-z · Cited by 3
“Recent studies suggest that “liquid biopsy” may also aid in cancer surveillance, as it may detect biomarkers such as ctDNA before clinical symptoms appear [119, 120].”
Recent advances in molecular diagnostics and therapeutic targets for pancreatic cancer
Clay, R., & Siddiqi, S. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819457-7.00016-5 · Cited by 3
Pancreatic Cancer Screening among High-risk Individuals
Turner, K. M., & Patel, S. H. (2024) · Surgical Clinics of North America · doi:10.1016/j.suc.2024.03.002 · Cited by 3
Lokhande, L., Emruli, V. K., Kolstad, A., Hutchings, M., Räty, R., Jerkeman, M., & Ek, S. (2020) · BMC Cancer · doi:10.1186/s12885-020-07678-4 · Cited by 3
Histone-based liquid biopsy discriminates between myelodysplastic syndrome and solid malignancies
Tsoneva, D. K., Búzová, D., Bianco, S. D., Micheva, I., Efraim, M. E., Daskalova, N., Resnick, I. B., Teneva, M., Chervenkov, T., Conev, N. V., et al. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01995-w · Cited by 2
“Regarding minimally invasive biomarkers’ evaluation, individual ones are widely used but may lack specificity and/or sensitivity in the early disease stages [13–16], rendering composite serum biomarker signatures a more promising diagnostic approach [17–19].”
Biomarkers in Pancreatic Cancer
Ansari, D., & Andersson, R. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_31 · Cited by 2
New‐onset Diabetes as a Harbinger of Pancreatic Cancer: is Early Diagnosis Possible?
Andersen, D. K., Chari, S. T., Costello, E., Crnogorac‐Jurcevic, T., Hart, P. A., Maitra, A., & Pandol, S. J. (2021) · Wiley eBooks · doi:10.1002/9781119570097.ch51 · Cited by 2
Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals
Labiner, A. J., Aronson, A., & Lucas, A. L. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.06.004 · Cited by 1
Role of Innate Immunity in Cancer
Joseph, A. M., Aiyan, A. A., Kumari, R., George, A. J. T., & Kishore, U. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-85340-1_13 · Cited by 1
Worthington, C., Raitses‐Gurevich, M., Innamorati, G., Hart, P. A., Wilkie, T. M., Tau, N., Brin, D., Yablecovitch, D., Laish, I., Keith, D., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70592 · Cited by 1
The Screening and Early Detection of Pancreatic Cancer: Who, When, and How?
Chang, J. H. (2020) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2020.25.2.65 · Cited by 1
Pancreatic cancer, pancreatogenic diabetes, type 2 diabetes mellitus
Друк, И. В. (2022) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-205-9-171-182 · Cited by 1
Clementine, R., Mas, L., Granier, S., Colle, E., Neuzillet, C., & Hammel, P. R. (2019) · Cancer Reports and Reviews · doi:10.15761/crr.1000184 · Cited by 1
“[33] proposed a proteomic multiparametric analysis including 29 biomarkers (mainly targeting the tumor secretome or immunoregulatory proteins to reflect the systemic response) to discriminate early stage PDAC (I or II) from healthy controls with an AUC/sensitivity/specificity of 0.”
MethodLiquid biopsy-based biomarkers for early detection of pancreatic cancer
Fahrmann, J. F., Capello, M., & Hanash, S. (2018) · Precision Cancer Medicine · doi:10.21037/pcm.2018.10.01 · Cited by 1
Nene, N. R., Ney, A., Nazarenko, T., Blyuss, O. B., Johnston, H. E., Whitwell, H. J., Sedlak, E., Gentry‐Maharaj, A., Costello, E., Greenhalf, W., et al. (2021) · medRxiv · doi:10.1101/2021.12.02.21267187 · Cited by 1
Spitzberg, J. D., Ferguson, S. W., Yang, K. S., Peterson, H. M., Carlson, J., & Weissleder, R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.17.496607 · Cited by 1
Bestari, M. B., Joewono, I. R., & Syam, A. F. (2023) · Preprints.org · doi:10.20944/preprints202312.2276.v1
Challenges and Opportunities for Early Pancreatic Cancer Detection: Role for Protein Biomarkers
Oldfield, L. S., Barrera, L. N., Williams, D., Evans, A., Neoptolemos, J. P., & Costello, E. (2020) · Molecular and translational medicine · doi:10.1007/978-3-030-49476-6_4
Ultrasensitive DNA sequencing using liquid biopsies enables precision medicine
Johansson, G. (2021) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Screening of Pancreatic Cancer for Early Diagnosis
Chang, J. H. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.2.110
Observational study on serum markers and circulating tumor cells in ovarian cancer
Jaiswal, R., Tripathi, P., Venkatesh, V., & Gupta, P. (2021) · IP Archives of Cytology and Histopathology Research · doi:10.18231/j.achr.2021.041
Etiology and early detection of pancreatic cancer
Yu, J. (2021) · Figshare
Jacob, H. K. C., Signorelli, R., Richard, J. L. C., Kashuv, T., Lavania, S., Middleton, A. N., Gomez, B. A., Ferrantella, A. R., Amirian, H., Tao, J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1489466/v1
The Tumor and Its Microenvironment as Complementary Sources of Cancer Biomarkers
Roy, R., Man, E., Aldakhlallah, R., Rashes, E. R., & Moses, M. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_22
Liang, H., Remstein, R., & LEWIS, D. (2022) · Springer eBooks · doi:10.1007/978-3-030-41683-6_44
Tsutsumi, K., & Otsuka, M. (2023) · Clinical and Translational Discovery · doi:10.1002/ctd2.177
Screening for Early Diagnosis of Pancreatic Cancer
Hanada, K., Shimizu, A., Tsushima, K., Ikeda, M., & Tazuma, S. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.250
Xiong, F., Wu, G., Wang, B., & Chen, Y. (2021) · Figshare · doi:10.6084/m9.figshare.15109914
DNA Nanotechnology‐Based Microfluidics for Liquid Biopsy
Niu, Q., Huang, S., Yang, C. J., & Wu, L. (2024) · Wiley eBooks · doi:10.1002/9783527840816.ch4
Early Detection of Sporadic Pancreatic Cancer
Scherübl, H., Andersson, R. E., Ansari, D., Esposito, I., Hackert, T., & Löhr, M. J. (2025) · Visceral Medicine · doi:10.1159/000545424
“The PANFAM study using a panel of immunological markers [19, 20] unfortunately was not successful.”
Rahman, M. M., Ferdous, J., & Ahmad, H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26608-9.00015-9
Lokhande, L., Emruli, V. K., Kolstad, A., Hutchings, M., Räty, R., Jerkeman, M., & Ek, S. (2020) · Figshare · doi:10.6084/m9.figshare.13346998
Lokhande, L., Emruli, V. K., Kolstad, A., Hutchings, M., Räty, R., Jerkeman, M., & Ek, S. (2020) · Figshare · doi:10.6084/m9.figshare.13346992
Jacob, H. K. C., Signorelli, R., Richard, J. L. C., Kashuv, T., Lavania, S., Middleton, A. N., Gomez, B. A., Ferrantella, A. R., Amirian, H., Tao, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20626352
Lokhande, L., Emruli, V. K., Kolstad, A., Hutchings, M., Räty, R., Jerkeman, M., & Ek, S. (2020) · Figshare · doi:10.6084/m9.figshare.13346989
Lokhande, L., Emruli, V. K., Kolstad, A., Hutchings, M., Räty, R., Jerkeman, M., & Ek, S. (2020) · Figshare · doi:10.6084/m9.figshare.13346995
Lokhande, L., Emruli, V. K., Kolstad, A., Hutchings, M., Räty, R., Jerkeman, M., & Ek, S. (2020) · Figshare · doi:10.6084/m9.figshare.13346986
Xiong, F., Wu, G.-H., Wang, B., & Chen, Y.-J. (2021) · Figshare · doi:10.6084/m9.figshare.15109917
Lokhande, L., Emruli, V. K., Kolstad, A., Hutchings, M., Räty, R., Jerkeman, M., & Ek, S. (2020) · Figshare · doi:10.6084/m9.figshare.13346983
Moldovan, S. A., Iacobescu, M., Moiș, E. I., Graur, F., Furcea, L., Zaharie, F. V., Ciocan, A., Soporan, M.-A., Pralea, I.-E., Mirel, S., et al. (2026) · Medicina · doi:10.3390/medicina62030605
“Recent plasma and serum proteomic investigations demonstrate that multi-protein signatures can outperform CA19-9 alone for diagnostic applications in PDAC [13,21].”
Zhu, Y., Zhu, L., Liu, Y., Ji, Y., Zhu, J., & Zhao, H. (2026) · PLoS ONE · doi:10.1371/journal.pone.0348699
“Finally, rigorous multi-cohort validation across diverse patient populations and technological platforms is rarely implemented, limiting the real-world applicability of proposed diagnostic panels [26,27].”
Hermoso‐Durán, S., Johansen, A. Z., Johansen, J. S., Feltoft, C. L., Hansen, C. P., Falcó-Martí, F. J., Fraunhoffer, N. A., Sanchez‐Gracia, O., Garrido, P. F., Vega, S., et al. (2026) · Intelligent Medicine · doi:10.1016/j.imed.2026.07.002
The effect of InGaN quantum wells on cancer detection by surface-enhanced Raman spectroscopy
Doan, K. H. T., Nhat, H. K., Tu, C.-D., Chien, F., Fu, P.-K., Chiu, Y., & Lai, K. (2026) · Chinese Journal of Physics · doi:10.1016/j.cjph.2026.07.026
Stable circulating histone complexes for minimally invasive liquid biopsy diagnostics
Kaštánková, N., Búzová, D., Vinciguerra, M., Lochmanová, G., Zdráhal, Z., Červený, J., & Fröhlich, J. (2026) · Epigenetics Reports · doi:10.1080/28361512.2026.2745851
Liquid biopsy in pancreatic ductal adenocarcinoma from diagnostic accuracy to clinical utility
Kossenas, K., Garmpis, N., Karountzos, N., & Damaskos, C. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1962181
“Mellby et al. ’ s 29-protein signature achieved AUC 0.96 for stage I – II disease in discovery and independent validation cohorts, but both were case-control studies (35).”
InfluentialGarcía-Gómez, J., Agredano-Pérez, S., Rubio-Delgado, D. A., Aguilar‐Lemarroy, A., Jave‐Suárez, L. F., Guevara-Hernández, S. N., Bravo‐Cuéllar, A., Méndez-Clemente, A. S., Hernández‐Flores, G., & Villaseñor-Garcı́a, M. M. (2026) · Biomolecules · doi:10.3390/biom16101492
“…have driven a search for better circulating markers, from the addition of thrombospondin-2 to CA19-9 [23] and multi-marker serum signatures [24] to liquid biopsies pairing circulating tumor DNA with proteins [25] or profiling tumor-derived extracellular vesicles, by their protein content…”
Wang, R., Li, C., Liu, W., Cai, Z., Ding, X., & Chongyi, J. (2026) · Small · doi:10.1002/smll.76296
Metadata
- Authors
- Mellby, L. D., Nyberg, A. P., Johansen, J. S., Wingren, C., Nordestgaard, B. G., Bojesen, S. E., Mitchell, B. L., Sheppard, B. C., Sears, R. C., & Borrebaeck, C. A. K.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Borrebaeck, Carl A.K.
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2018-10-01
- Volume
- 36
- Issue
- 28
- Pages
- 2887-2894
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC6161836
- OpenAlex
- W2887694233
- Cited by
- 159
- References
- 52
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 20 · 2023: 17 · 2022: 20 · 2021: 39 · 2020: 25 · 2019: 13 · 2018: 2
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Gentofte Hospital
- Rigshospitalet
- National Institutes of Health (UL1TR002369)
- National Cancer Institute (R01CA196228, R01CA186241)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic ductal adenocarcinoma, early-stage pancreatic cancer, liquid biopsy, cancer detection, antibody microarrays, diagnostic biomarkers, tumor staging
- MeSH terms
- Liquid Biopsy, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Retrospective Studies, Sensitivity and Specificity, Biomarkers, Tumor, Cohort Studies, Case-Control Studies, Carcinoma, Pancreatic Ductal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
